Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
Christian Ulrich von Linstow, Ziv Gan‐Or, Patrik Brundin
Translational Neurodegeneration (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis
Mehar Sahu, Rohan Gupta, Rashmi K. Ambasta, et al.
Progress in molecular biology and translational science (2022), pp. 57-100
Closed Access | Times Cited: 92
Perspective of artificial intelligence in healthcare data management: A journey towards precision medicine
Nancy Sanjay Gupta, Pravir Kumar
Computers in Biology and Medicine (2023) Vol. 162, pp. 107051-107051
Closed Access | Times Cited: 70
A blood-based marker of mitochondrial DNA damage in Parkinson’s disease
Rui Qi, Esther Sammler, Claudia P. González-Hunt, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 711
Open Access | Times Cited: 43
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 3
Short Chain Fatty Acid Metabolism in Relation to Gut Microbiota and Genetic Variability
Guilherme Ramos Meyers, Hanen Samouda, Torsten Bohn
Nutrients (2022) Vol. 14, Iss. 24, pp. 5361-5361
Open Access | Times Cited: 69
Prodromal Parkinson's disease: hype or hope for disease-modification trials?
Philipp Mahlknecht, Kathrin Marini, Mario Werkmann, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 49
Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
Holger Fröhlich, Noémi Bontridder, Dijana Petrovska-Delacréta, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 44
LRRK2 and Parkinson's disease: from genetics to targeted therapy
Yuri L. Sosero, Ziv Gan‐Or
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 6, pp. 850-864
Open Access | Times Cited: 35
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Angeliki Zarkali, George E. Thomas, Henrik Zetterberg, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Xuxiang Zhang, Heng Wu, Beisha Tang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Konstantin Senkevich, Uladzislau Rudakou, Ziv Gan‐Or
Neuropharmacology (2021) Vol. 202, pp. 108822-108822
Closed Access | Times Cited: 54
COVID-19 and Parkinsonism: A Critical Appraisal
Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, et al.
Biomolecules (2022) Vol. 12, Iss. 7, pp. 970-970
Open Access | Times Cited: 26
Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician’s Perspective
Andrea Sturchio, Emily M. Rocha, Marcelo Kauffman, et al.
Brain Sciences (2024) Vol. 14, Iss. 2, pp. 151-151
Open Access | Times Cited: 6
Pharmacotherapy for Disease Modification in Early Parkinson’s Disease: How Early Should We Be?
Philipp Mahlknecht, Werner Poewe
Journal of Parkinson s Disease (2024) Vol. 14, Iss. s2, pp. S407-S421
Open Access | Times Cited: 5
Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases
Valentina La Cognata, Giovanna Morello, Sebastiano Cavallaro
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4820-4820
Open Access | Times Cited: 32
Polygenic Risk Scores Contribute to Personalized Medicine of Parkinson’s Disease
Mohammad Dehestani, Hui Liu, Thomas Gasser
Journal of Personalized Medicine (2021) Vol. 11, Iss. 10, pp. 1030-1030
Open Access | Times Cited: 25
International Genetic Testing and Counseling Practices for Parkinson's Disease
Rachel Saunders‐Pullman, Deborah Raymond, Roberto A. Ortega, et al.
Movement Disorders (2023) Vol. 38, Iss. 8, pp. 1527-1535
Closed Access | Times Cited: 10
Luxembourg Parkinson’s study -comprehensive baseline analysis of Parkinson’s disease and atypical parkinsonism
Lukas Pavelka, Rajesh Rawal, Soumyabrata Ghosh, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 10
Aberrant Structure MRI in Parkinson’s Disease and Comorbidity with Depression Based on Multinomial Tensor Regression Analysis
Xuan Cao, Fang Yang, Jingyi Zheng, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 89-89
Open Access | Times Cited: 13
Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernández-Díaz, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 12
Astrocytes Differentiated from LRRK2-I1371V Parkinson’s-Disease-Induced Pluripotent Stem Cells Exhibit Similar Yield but Cell-Intrinsic Dysfunction in Glutamate Uptake and Metabolism, ATP Generation, and Nrf2-Mediated Glutathione Machinery
Roon Banerjee, Aishwarya Raj, Chandrakanta Potdar, et al.
Cells (2023) Vol. 12, Iss. 12, pp. 1592-1592
Open Access | Times Cited: 6
Dopaminergic Neurons Differentiated from LRRK2 I1371V-Induced Pluripotent Stem Cells Display a Lower Yield, α-Synuclein Pathology, and Functional Impairment
Soham Jagtap, Chandrakanta Potdar, Ravi Yadav, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 17, pp. 2632-2645
Closed Access | Times Cited: 9
Who to Enroll in Parkinson Disease Prevention Trials?
Kellyann Niotis, Andrew B. West, Rachel Saunders‐Pullman
Neurology (2022) Vol. 99, Iss. 7_Supplement_1, pp. 10-18
Open Access | Times Cited: 8
Precision medicine for Parkinson’s disease: The subtyping challenge
Mark Frasier, Brian Fiske, Todd Sherer
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 8
Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
Robert K. Leśniak, R. Jeremy Nichols, Thomas J. Montine
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top